Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Liabilities and Shareholders Equity (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $190.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 12.21% year-over-year to $190.6 million, compared with a TTM value of $799.5 million through Dec 2025, down 11.06%, and an annual FY2025 reading of $190.6 million, down 12.21% over the prior year.
  • Liabilities and Shareholders Equity was $190.6 million for Q4 2025 at Treace Medical Concepts, down from $196.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $251.9 million in Q4 2023 and bottomed at $37.4 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $188.4 million, with a median of $201.2 million recorded in 2025.
  • The sharpest move saw Liabilities and Shareholders Equity surged 291.93% in 2022, then dropped 15.19% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $140.8 million in 2021, then rose by 12.93% to $159.0 million in 2022, then surged by 58.41% to $251.9 million in 2023, then decreased by 13.82% to $217.1 million in 2024, then fell by 12.21% to $190.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for TMCI at $190.6 million in Q4 2025, $196.6 million in Q3 2025, and $206.4 million in Q2 2025.